Helicobacter pylori treatment in the era of increasing antibiotic resistance

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• The standard triple therapy for Helicobacter pylori eradication, comprising a proton pump inhibitor (PPI), amoxicillin, and clarithromycin, is experiencing declining success rates worldwide.
• Local eradication rates for this common regimen are often unacceptably low, rendering consensus guidelines potentially unreliable.

Purpose of the Study:

• To evaluate the current efficacy of standard H. pylori eradication regimens.
• To provide guidance on selecting effective H. pylori treatment strategies based on local data and evidence-based outcomes.

Main Methods:

• Review of worldwide results on H. pylori eradication therapies.
• Analysis of treatment success rates for various therapeutic regimens, including triple, quadruple, and sequential therapies.

Main Results:

• The commonly recommended triple therapy (PPI, amoxicillin, clarithromycin) demonstrates unacceptably low and inconsistent treatment success across populations.
• Alternative regimens such as 14-day concomitant quadruple therapy, 10-day sequential treatment, or 14-day bismuth-containing quadruple therapy show promise where triple therapy fails.

Conclusions:

• Clinicians should prioritize local eradication data over generalized guidelines when selecting H. pylori treatment.
• Effective H. pylori eradication requires a shift towards alternative regimens when standard triple therapy proves ineffective locally.
• Future clinical trials must focus on identifying and comparing novel regimens against locally effective treatments or untreated controls to ensure ethical and meaningful results.